Breaking News Instant updates and real-time market news.

ADMP

Adamis Pharmaceuticals

$1.30

0.04 (3.17%)

, NVS

Novartis

$90.76

0.29 (0.32%)

08:35
07/09/19
07/09
08:35
07/09/19
08:35

Adamis Pharmaceuticals provides update on U.S. retail launch of SYMJEPI

Adamis Pharmaceuticals Corporation (ADMP) provided an update that Sandoz, a Novartis (NVS) division, announced the U.S. retail launch of SYMJEPI 0.3 mg and 0.15 mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the U.S. Sandoz launched SYMJEPI 0.3 mg Injection in the institutional channel earlier this year, and large wholesaler customers of Sandoz are now fully stocked to supply hospitals and clinics with both SYMJEPI 0.3 mg and 0.15 mg Injections inventory in the U.S.

ADMP

Adamis Pharmaceuticals

$1.30

0.04 (3.17%)

NVS

Novartis

$90.76

0.29 (0.32%)

  • 11

    Jul

  • 22

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Sep

ADMP Adamis Pharmaceuticals
$1.30

0.04 (3.17%)

08/23/18
HCWC
08/23/18
NO CHANGE
Target $7
HCWC
Buy
Adamis selloff on generic EpiPen a buying opportunity, says H.C. Wainwright
Recent weakness in shares of Adamis Pharmaceuticals (ADMP) appears related to news that Teva (TEVA) has received approval to launch a generic version of Mylan's (MYL) EpiPen, H.C. Wainwright analyst Jason Kolbert tells investors in a research note. Sandoz, Adamis' partner, is well aware of Teva's initiatives and remains committed to the launch of Adamis' Symjepi, the analyst adds, As such, he views the recent pullback in Adamis as a buying opportunity. He lowered his price target for the stock to $7 from $10 and keeps a Buy rating on the name.
11/12/18
RILY
11/12/18
DOWNGRADE
Target $2.5
RILY
Neutral
Adamis Pharmaceuticals downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva downgraded Adamis Pharmaceuticals to Neutral and lowered his price target for the shares to $2.50 from $7.50. The analyst cites the company's Q3 results for moving him to the sidelines.
NVS Novartis
$90.76

0.29 (0.32%)

06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.

TODAY'S FREE FLY STORIES

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.10

1.02 (5.97%)

17:05
08/19/19
08/19
17:05
08/19/19
17:05
Hot Stocks
Breaking Hot Stocks news story on iQIYI »

iQIYI down over 6% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

17:03
08/19/19
08/19
17:03
08/19/19
17:03
Hot Stocks
iQIYI reports Q2 total subscribing members 100.5M, up 50% from last year »

iQIYI's number of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.